Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr-Jun;42(2):115-124.
doi: 10.12865/CHSJ.42.02.01. Epub 2016 Jun 28.

Adalimumab and Infliximab in Crohn's disease - real life data from a national retrospective cohort study

C Preda  1 , L Fulger  1 , L Gheorghe  1 , C Gheorghe  1 , A Goldis  2 , A Trifan  3 , M Tantau  4 , A Tantau  4 , L Negreanu  5 , M Manuc  1 , C Cijevschi-Prelipcean  3 , R Iacob  1 , C Tieranu  1 , C Meianu  1 , M Diculescu  1
Affiliations

Adalimumab and Infliximab in Crohn's disease - real life data from a national retrospective cohort study

C Preda et al. Curr Health Sci J. 2016 Apr-Jun.

Abstract

Aim: to compare the efficacy and safety of Adalimumab(ADA) and Infliximab(IFX), in a large Romanian population and to identify predictors of response. Methods We performed a national retrospective cohort study including 265 patients (136 ADA, 129 IFX) between 2008-2014. Binary logistic regression was performed with the statistical program Minitab.

Results: Patients were half women, with a median age of 36, a median disease duration of 2.5 years, 80% received Azathioprine. Mean therapy duration was 20 months in ADA group and 36 months in IFX group. Complete response to Adalimumab respectively Infliximab was recorded in 77%vs.65%, secondary loss of response in 18%vs.28%, statistically comparable. We failed to identify predictors of response. In 79.2%of patients with secondary loss of response to ADA, the dose was escalated, 12.5% were switched to Infliximab. In 70%of patients that lost response to IFX, the dose was increased, 30% were switched to Adalimumab.

Conclusions: Adalimumab and Infliximab have similar efficacy, with a complete response rate of~70%. In case of secondary loss of response to IFX, the best solution is to switch to ADA, with 83% response rate, while in case of secondary loss of response to ADA, increasing the dose leads to 84 % response rate.

Keywords: Adalimumab; Crohn's disease; Infliximab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Rate of complete response in time in patients with Crohn's disease treated with Adalimumab/Infliximab
Figure 2
Figure 2
Outcome of patients with Crohn’s disease treated with Adalimumab
Figure 3
Figure 3
Outcome of patients with Crohn’s disease treated with Infliximab
See this image and copyright information in PMC

References

    1. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. for the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis. 2010;4:7–27. - PubMed
    1. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, L�fberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512–530. - PubMed
    1. D'Haens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660–667. - PubMed
    1. Dignass A, Van Assche G, Lindsay JO, L�mann M, S�derholm J, Colombel JF, et al. for the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis. 2010;4:28–62. - PubMed
    1. Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol. 2013;6(4):269–293. - PMC - PubMed

LinkOut - more resources